208 related articles for article (PubMed ID: 10076915)
21. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
Fridman K; Andersson OK; Wysocki M; Friberg P; Sunzel M
Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289
[TBL] [Abstract][Full Text] [Related]
22. Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension.
Oparil S
Am J Cardiol; 1999 Nov; 84(10A):35S-41S. PubMed ID: 10588093
[TBL] [Abstract][Full Text] [Related]
23. Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility.
Mengden T; Uen S; Bramlage P
Vasc Health Risk Manag; 2009; 5():1043-58. PubMed ID: 20057897
[TBL] [Abstract][Full Text] [Related]
24. Achieving quality 24-h blood pressure control with candesartan cilexetil.
Meredith P
Blood Press Suppl; 2000; 1():23-6. PubMed ID: 11059632
[TBL] [Abstract][Full Text] [Related]
25. Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.
Inada Y; Ojima M; Kanagawa R; Misumi Y; Nishikawa K; Naka T
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S75-80. PubMed ID: 10076925
[TBL] [Abstract][Full Text] [Related]
26. Candesartan plus hydrochlorothiazide: an overview of its use and efficacy.
Mugellini A; Nieswandt V
Expert Opin Pharmacother; 2012 Dec; 13(18):2699-709. PubMed ID: 23170938
[TBL] [Abstract][Full Text] [Related]
27. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators.
Kloner RA; Weinberger M; Pool JL; Chrysant SG; Prasad R; Harris SM; Zyczynski TM; Leidy NK; Michelson EL;
Am J Cardiol; 2001 Mar; 87(6):727-31. PubMed ID: 11249891
[TBL] [Abstract][Full Text] [Related]
28. Putting the efficacy of candesartan cilexetil into perspective: a review of new comparative data.
Mallion JM; Badguet JP
J Hum Hypertens; 2000 Oct; 14 Suppl 2():S33-41. PubMed ID: 11086634
[TBL] [Abstract][Full Text] [Related]
29. Effects of candesartan cilexetil in patients with systemic hypertension. Candesartan Cilexetil Study Investigators.
Reif M; White WB; Fagan TC; Oparil S; Flanagan TL; Edwards DT; Cushing DJ; Michelson EL
Am J Cardiol; 1998 Oct; 82(8):961-5. PubMed ID: 9794352
[TBL] [Abstract][Full Text] [Related]
30. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
Baguet JP; Nisse-Durgeat S; Mouret S; Asmar R; Mallion JM
Int J Clin Pract; 2006 Apr; 60(4):391-8. PubMed ID: 16620350
[TBL] [Abstract][Full Text] [Related]
31. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
McInnes GT; O'Kane KP; Jonker J; Roth J
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S75-80. PubMed ID: 9331015
[TBL] [Abstract][Full Text] [Related]
32. Tolerability of a modern antihypertensive agent: candesartan cilexetil.
Andersson OK
Basic Res Cardiol; 1998; 93 Suppl 2():54-8. PubMed ID: 9833164
[TBL] [Abstract][Full Text] [Related]
33. Improving prognosis in hypertension: exploring the benefits of angiotensin II type 1 receptor blockade.
Ruilope L
Blood Press Suppl; 2000; 1():31-5. PubMed ID: 11059634
[TBL] [Abstract][Full Text] [Related]
34. [Candesartan cilexetil: pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist].
Inada Y; Naka T
Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):151-60. PubMed ID: 10876800
[TBL] [Abstract][Full Text] [Related]
35. [Angiotensin receptor antagonist for therapy of patients with hypertension].
Rakugi H; Ogihara T
Nihon Rinsho; 1997 Aug; 55(8):2075-80. PubMed ID: 9284426
[TBL] [Abstract][Full Text] [Related]
36. Antihypertensive treatment in elderly patients aged 75 years or over: a 24-week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide.
Neldam S; Forsén B;
Drugs Aging; 2001; 18(3):225-32. PubMed ID: 11302289
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators.
Weir MR; Weber MA; Neutel JM; Vendetti J; Michelson EL; Wang RY
Am J Hypertens; 2001 Jun; 14(6 Pt 1):567-72. PubMed ID: 11411737
[TBL] [Abstract][Full Text] [Related]
38. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators.
Riegger GA; Bouzo H; Petr P; Münz J; Spacek R; Pethig H; von Behren V; George M; Arens H
Circulation; 1999 Nov; 100(22):2224-30. PubMed ID: 10577995
[TBL] [Abstract][Full Text] [Related]
39. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
Israili ZH
J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
[TBL] [Abstract][Full Text] [Related]
40. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
Bönner G; Fuchs W
Curr Med Res Opin; 2005 Jun; 21(6):935-40. PubMed ID: 15969893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
